Viatris Inc
Change company Symbol lookup
Select an option...
VTRS Viatris Inc
RIV-A RiverNorth Opportunities Fund Inc
ARKF ARK Fintech Innovation ETF
TRNS Transcat Inc
CDXI Cardax Inc
PGYC Patriot Energy Corp (Texas)
ISRG Intuitive Surgical Inc
SPH Suburban Propane Partners LP
PBYI Puma Biotechnology Inc
GOLF Acushnet Holdings Corp
Go

Health Care : Pharmaceuticals | Mid Cap Value
Company profile

Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Closing Price
$12.25
Day's Change
0.24 (2.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
12.25
Day's Low
11.97
Volume
(Above Average)
Volume:
12,015,700

10-day average volume:
10,629,021
12,015,700

VTRS's position in the Pharmaceuticals industry

Industry PeersVTRSZTSCTLTAMPHSAVA

Summary

Company ProfileViatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily...
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health...
Go to ZTS summary
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include...
Go to CTLT summary
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and...
Go to AMPH summary
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The...
Go to SAVA summary
52-Week Change

VS. INDUSTRY
-19.09%
-1.47%
0.26%
104.47%
-52.05%
Market Cap

VS. INDUSTRY
$14.9B
$81.0B
$18.9B
$1.9B
$1.1B
Beta

VS. INDUSTRY
1.3
0.8
1.4
0.7
1.0
Dividend Yield

VS. INDUSTRY
3.92%
0.76%
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
89.50x
39.49x
37.94x
24.16x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$17.6B
$7.9B
$4.7B
$455.1M
$0.0
Profit Margin

VS. INDUSTRY
0.95%
26.23%
10.92%
18.57%
--
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
20.99%
28.57%
43.27%
--
Revenue Growth (TTM)

VS. INDUSTRY
28.28%
12.54%
25.17%
23.61%
--
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.